Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Paris M, Delev N, Teng L, Wollenhaupt J (2020)

Publication Type: Journal article

Publication year: 2020

Journal

ACR Open Rheumatology Wiley

Book Volume: 2

Pages Range: 459-470

Journal Issue: 8

DOI: 10.1002/acr2.11156

Abstract

ObjectivePsoriatic arthritis (PsA) requires long-term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) 1, 2, and 3 data describes 3-year apremilast safety and tolerability in PsA.

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Celgene Corporation US United States (USA) (US) Schön Klinik Hamburg Eilbek DE Germany (DE) Amgen Inc. US United States (USA) (US) Monash University AU Australia (AU) University of California, San Diego US United States (USA) (US) University of Orléans / Université d'Orléans FR France (FR) Toronto Western Hospital CA Canada (CA) Swedish Medical Center US United States (USA) (US) Complejo Hospitalario Universitario de Santiago de Compostela ES Spain (ES)

How to cite

APA:

Mease, P.J., Gladman, D.D., Gomez-Reino, J.J., Hall, S., Kavanaugh, A., Lespessailles, E.,... Wollenhaupt, J. (2020). Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. ACR Open Rheumatology, 2(8), 459-470. https://doi.org/10.1002/acr2.11156

MLA:

Mease, Philip J., et al. "Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials." ACR Open Rheumatology 2.8 (2020): 459-470.

BibTeX: Download